Publications

cemka > Publications

Classer les publications sur l'année

  • BiomĂ©trie et Analyses de bases de donnĂ©es/SNDS

    Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis.

    NEUZILLET C, EMERY C, TEISSIER C, BOUEE S, LIEVRE A.

    Lancet Reg Health Eur ; 2022;15:100324

  • BiomĂ©trie et Analyses de bases de donnĂ©es/SNDS

    Costs and management of patients with hemophilia A in France: the Hemraude study.

    LAURENDEAU C, GOUDEMAND J, TROSSAERT M, POLACK B, VARIN R, GODARD C, HADIM F, DETOURNAY B.

    Eur J Health Econ. ; 2022;23(1):23-32

  • BiomĂ©trie et Analyses de bases de donnĂ©es/SNDS

    Correction to: Long-Term Mortality and State Financial Support in Invasive Meningococcal Disease-Real-World Data Analysis Using the French National Claims Database (SNIIRAM)

    SHEN J, BOUEE S, ARIS E, EMERY C, BECK EC.

    Infect Dis Ther ; 2022;11(1):263-264

  • BiomĂ©trie et Analyses de bases de donnĂ©es/SNDS

    Trends in postmenopausal osteoporosis treatment in France during the period 2007-2016: A nationwide claim database analysis.

    CORTET B, SCHOTT AM, DESAMERICQ G, CHAUNY JV, SAMAMA P, EMERY C, FAGNANI F.

    Bone ; 2022;154:116255

  • BiomĂ©trie et Analyses de bases de donnĂ©es/SNDS

    Non‑tuberculous mycobacterial pulmonary diseases in France: an 8 years nationwide study

    VEZIRIS N, ANDREJAK C, BOUEE S, EMERY C, OBRADOVIC M, CHIRON R.

    BMC Infectious Diseases ; 2021;21(1):1165

  • Pharmaco-EpidĂ©miologie

    Quality of life in SSc-ILD patients: Understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France.

    ALLANORE Y, CONSTANS J, GODARD D, DE POUVOURVILLE G, BOUEE S, JEANBAT V, TEISSIER C, LE LAY K, CHOLLET J, HACHULLA E.

    J Scleroderma Related Disorders ; 2022;7(1):49-56

  • Économie de la santĂ©

    France’s competitiveness in global pharmaceutical research: The situation is improving

    D’ANDON A, GALAUP A, FABRON C, DETOURNAY B, BOREL T.

    Therapies ; 2021;76(6):549-557

  • Économie de la santĂ©

    Le systĂšme de santĂ© français aujourd’hui – Enjeux et dĂ©fis : Mieux mobiliser l’évaluation Ă©conomique pour rĂ©guler les dĂ©penses de santĂ©.

    BONASTRE J, DETOURNAY B, SERRIER H.

    Revue du CollÚge des économistes de la santé ; 2021:65-80

  • Économie de la santĂ©

    Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study.

    ROUSSEL R, RIVELINE JP, VICAUT E, DE POUVOURVILLE G, DETOURNAY B, EMERY C, LEVRAT-GUILLEN F, GUERCI B.

    Diabetes Care ; 2021;44(6):1368-1376

  • BiomĂ©trie et Analyses de bases de donnĂ©es/SNDS

    Prevalence and management of chronic nodular prurigo (CNPG) in Brittany (France): estimation by matching two databases.

    MISERY L, BRENAUT E, TORRETON E, BONTE J, BOUEE S.

    Journal of the European Academy of Dermatology and Venereology ; 2021;35(9):e602-e604

  • BiomĂ©trie et Analyses de bases de donnĂ©es/SNDS

    Risk factors for invasive meningococcal disease: a retrospective analysis of the French national public health insurance database

    TAHA M.-K , WEIL-OLIVIER C , BOUEE S, EMERY C , NACHBAUR G, PRIBIL C, LONCLE-PROVOT V.

    HUMAN VACCINES & IMMUNOTHERAPEUTICS ; 2021;17(6):1858-1866

  • BiomĂ©trie et Analyses de bases de donnĂ©es/SNDS

    Healthcare Resource Consumption and Cost of Invasive Meningococcal Disease in France: A Study of the National Health Insurance Database

    WEIL-OLIVIER C, TAHA M-K, EMERY C, BOUEE S, BECK E, ARIS E, LONCLE-PROVOT V, NACHBAUR G, PRIBIL C.

    Infectious Diseases and Therapy ; 2021;10(3):1607-1623

  • Économie de la santĂ©

    ConsĂ©quences Ă©conomiques du non-respect des rĂšgles d’arrĂȘt des agonistes des rĂ©cepteurs du GLP-1 au moment du passage Ă  l’insuline en France

    DETOURNAY B, SAFSAF, S, BAHLOUL A, CHARBONNEL B.

    Med Mal Metab ; 2021;15(5):537-541

  • BiomĂ©trie et Analyses de bases de donnĂ©es/SNDS

    Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study

    GIRARD N, MORO-SIBILOT D, BOUEE S, EMERY C, TORRETON E, LE LAY K, LUCIANI L, MARITAZ C, CHOUAID C

    Future Oncol ; 2020;16(16),1115-1124

  • BiomĂ©trie et Analyses de bases de donnĂ©es/SNDS

    An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017

    VERMERSCH P, SUCHET L, COLAMOARINO R, LAURENDEAU C, DETOURNAY B

    Mult Scler Relat Disord ; 2020;46:102521